ArticlePloS one2011
FDA-approved drugs that protect mammalian neurons from glucose toxicity slow aging dependent on cbp and protect against proteotoxicity.
Article in PloS one, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed, 87 citations in OpenAlex.
- Cyrene: a novel geroprotective compound that extends lifespan and healthspan in C. elegans and Drosophila.npj aging · 2025Article
- Tannic acid inhibits TNF-α signaling by targeting the protein disulfide isomerase and alleviates symptoms in an imiquimod-induced psoriasis mouse model.Cell communication and signaling : CCS · 2025Article
- An mTOR inhibitor discovery system using drug-sensitized yeast.GeroScience · 2025Article
- Discovery of Small Molecule Glycolytic Stimulants for Enhanced ApoE Lipidation in Alzheimer's Disease Cell Model.Pharmaceuticals (Basel, Switzerland) · 2024Article
- Drug repurposing for neurodegenerative diseases using Zebrafish behavioral profiles.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2024Article
- Associations between genetically predicted plasma protein levels and Alzheimer's disease risk: a study using genetic prediction models.Alzheimer's research & therapy · 2024Article
- Mitophagy-promoting agents and their ability to promote healthy-aging.Biochemical Society transactions · 2023Article
- Cytochrome P450 and Epoxide Hydrolase Metabolites in Aβ and tau-induced Neurodegeneration: Insights frombioRxiv : the preprint server for biology · 2023Article
- Toxicology of pharmaceutical and nutritional longevity compounds.Expert reviews in molecular medicine · 2023Review
- Therapeutics That Can Potentially Replicate or Augment the Anti-Aging Effects of Physical Exercise.International journal of molecular sciences · 2022Review
- Article
- UsingFrontiers in pharmacology · 2022Review
- Bioactive Phytochemicals with Anti-Aging and Lifespan Extending Potentials inMolecules (Basel, Switzerland) · 2021Review
- Iron: an underrated factor in aging.Aging · 2021Article
- Dietary thiols accelerate aging of C. elegans.Nature communications · 2021Article
- Biotechnological Insights on the Expression and Production of Antimicrobial Peptides in Plants.Molecules (Basel, Switzerland) · 2021Review
- Modifiable Risk Factors in Alzheimer Disease and Related Dementias: A Review.Clinical therapeutics · 2021Review
- Drug discovery: Insights from the invertebrate Caenorhabditis elegans.Pharmacology research & perspectives · 2021Review
- Preventive and Therapeutic Strategies in Alzheimer's Disease: Focus on Oxidative Stress, Redox Metals, and Ferroptosis.Antioxidants & redox signaling · 2021Review
- Reposition of the Fungicide Ciclopirox for Cancer Treatment.Recent patents on anti-cancer drug discovery · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
Abstract
Screening a library of drugs with known safety profiles in humans yielded 30 drugs that reliably protected mammalian neurons against glucose toxicity. Subsequent screening demonstrated that 6 of these 30 drugs increase lifespan in C. elegans: caffeine, ciclopirox olamine, tannic acid, acetaminophen, bacitracin, and baicalein. Every drug significantly reduced the age-dependent acceleration of mortality rate. These protective effects were blocked by RNAi inhibition of cbp-1 in adults only, which also blocks protective effects of dietary restriction. Only 2 drugs, caffeine and tannic acid, exhibited a similar dependency on DAF-16. Caffeine, tannic acid, and bacitracin also reduced pathology in a transgenic model of proteotoxicity associated with Alzheimer's disease. These results further support a key role for glucose toxicity in driving age-related pathologies and for CBP-1 in protection against age-related pathologies. These results also provide novel lead compounds with known safety profiles in human for treatment of age-related diseases, including Alzheimer's disease and diabetic complications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.